Japan Tobacco (2914) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
Jan–Sep revenue was ¥2,991.4bn, up 13.6% YoY; adjusted operating profit at constant FX rose 16.9%, led by Tobacco.
Strong pricing, share gains and Ploom growth supported higher FY2026 forecasts; attributable profit is projected to rise 32.6% YoY.
Financial highlights
Jan–Sep core revenue at constant FX was ¥2,732.3bn, up 8.4%; adjusted operating profit was ¥972.4bn, up 21.6%.
Operating profit was ¥947.7bn, up 24.2%; profit for the period was ¥621.5bn and attributable profit was ¥618.9bn, up 20.9%.
Tobacco core revenue was ¥2,750.5bn, up 14.5% reported and 8.7% at constant FX; adjusted operating profit was ¥1,005.4bn, up 21.1% and 16.6%, respectively.
Processed Food revenue rose ¥4.1bn YoY to ¥119.4bn; adjusted operating profit increased ¥0.4bn to ¥6.0bn.
Outlook and guidance
FY2026 revenue forecast is ¥3,903bn, up 12.6% YoY and ¥18bn above prior guidance; core revenue at constant FX is forecast at ¥3,558bn, up 7.3%.
Adjusted operating profit forecast rose ¥44bn to ¥1,079bn, up 21.9%; at constant FX it rose ¥40bn to ¥1,028bn, up 16.1%.
Operating profit forecast rose ¥33bn to ¥1,041bn, up 20.1%; attributable profit rose ¥18bn to ¥662bn, up 32.6%.
Tobacco volume is forecast to decline 0.5%; tobacco adjusted operating profit is forecast at ¥1,133bn, up 21.2%.
Processed Food revenue forecast was reduced ¥3bn to ¥167bn; adjusted operating profit forecast rose ¥0.5bn to ¥8.5bn.
Latest events from Japan Tobacco
- Strong H1 2026 results and upgraded outlook, driven by tobacco and RRP growth.2914
Q2 2026 - Q1 2026 delivered strong revenue and profit growth, with robust outlook and high dividend forecast.2914
Q1 2026 - Record-high profit and revenue in FY2025, with robust outlook and continued RRP expansion.2914
Q4 2025 - Record-high profit and revenue, higher guidance, and increased dividend after business divestiture.2914
Q3 2025 - Strong revenue and profit growth led to higher forecasts and dividend guidance for 2025.2914
Q2 2025 - Strong tobacco pricing and RRP growth drove higher profit and raised full-year guidance.2914
Q2 2024 - Revenue up 11% and US market share expanded via Vector, but profit faces cost and litigation risks.2914
Q3 2024 - Q1 2025 saw robust profit growth, pharma divestment to Shionogi, and steady dividend guidance.2914
Q1 2025 - Record revenue and profit growth in FY2024, with high single-digit AOP growth targeted for 2025.2914
Q4 2024